• 1
    Heffernan MP. Combining traditional systemic and biologic therapies for psoriasis. Semin Cutan Med Surg 2010; 29: 679.
  • 2
    Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl 2): 170.
  • 3
    Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 9216.
  • 4
    Driessen RJ, van de Kerkhof PC, de Jong EM. Etanercept combined with methotrexate for high-need psoriasis. 2008; 159(2): 4603.
  • 5
    Zachariae C, Mork NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL, Johannesson A, Clareus B, Skov L, Mork G, Walker S, Qvitzau S. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008; 88: 495501.
  • 6
    Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60: 100117.
  • 7
    O’Driscoll M, Jeggo PA. CsA can induce DNA double-strand breaks: implications for BMT regimens particularly for individuals with defective DNA repair. Bone Marrow Transplant 2008; 41: 9839.
  • 8
    Kuschal C, Thoms KM, Mori T, Kobayashi N, Boeckmann L, Laspe P, Emmert S. Cyclosporin A, but not everolimus, inhibits DNA repair in human fibroblasts and lymphoblasts. Int J Clin Pharmacol Ther 2009; 47: 3840.
  • 9
    Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC, Lamarque V, Dubertret L. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003; 120: 2116.
  • 10
    Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 288695.
  • 11
    Lee EJ, Shin MK, Kim NI. A clinical trial of combination therapy with etanercept and low dose cyclosporine for the treatment of refractory psoriasis. Ann Dermatol 2010; 22: 13842.
  • 12
    Yamauchi PS, Lowe NJ. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis. J Am Acad Dermatol 2006; 54: S1358.
  • 13
    D’Angelo S, Cutro MS, Lubrano E, Leccese P, Mennillo GA, Ferrara N, Olivieri I. Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis. Ann Rheum Dis 2010; 69: 9345.
  • 14
    Kress DW. Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis. J Am Acad Dermatol 2006; 54: S1268.
  • 15
    Conley J, Nanton J, Dhawan S, Pearce DJ, Feldman SR. Novel combination regimens: biologics and acitretin for the treatment of psoriasis – a case series. J Dermatolog Treat 2006; 17: 869.
  • 16
    Smith EC, Riddle C, Menter MA, Lebwohl M. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol 2008; 47: 5148.
  • 17
    Gisondi P, Del GM, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008; 158: 13459.
  • 18
    Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003; 49: 64450.